Bizarre giant cells in human angiosarcoma exhibit chemoresistance and contribute to poor survival outcomes

• DOI: 10.1111/cas.14726
• Publication Date: 2020-11-09T02:50:00Z
• Authors: Grace Fangmin Tan; Shane Goh; Abner Herbert Lim; Wei Liu; Jing Yi Lee; Vikneswari Rajase...; Xin Xiu Sam; Timothy Kwang Yon...; Sathiyamoorthy Se...; Cedric Chuan‐Youn...; Bin Tean Teh; Jason Yongsheng Chan
• Keywords: CD31

Giant cells (GC) are a poorly understood subset of tumor that have been increasingly recognized as potential contributor to heterogeneity and treatment resistance. We aimed characterize the biological clinical significance GC in angiosarcoma, an aggressive rare cancer endothelial origin. Archival angiosarcoma samples were examined for presence compared with clinicopathological well NanoString gene expression data. cell lines MOLAS ISOHAS using conventional electron microscopy, single whole genome profiling, other assays. In lines, represented population mitotically active, non-senescent CD31+ cells, shared similar genomic profiles regular-sized consistent malignant phenotype. remained viable persisted culture following exposure paclitaxel doxorubicin. patient samples, present 24 58 (41.4%) cases. was correlated poorer responses chemotherapy (25.0% vs 73.3%, P = 0.0213) independently contributed worse overall survival outcomes (hazard ratio 2.20, 95% confidence interval 1.17-4.15, 0.0142). profiling revealed overexpression genes, including COL11A1, STC1, ERO1A, accompanied by upregulation immune-related metabolic stress metastasis/matrix remodeling pathways GC-containing tumors. conclusion, may contribute chemoresistance poor prognosis angiosarcoma.